ClinConnect ClinConnect Logo
Search / Trial NCT06577857

Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study

Launched by SANOCULIS LTD · Aug 27, 2024

Trial Information

Current as of July 21, 2025

Recruiting

Keywords

Intraocular Pressure Mims Inferonasal Minimally Invasive Glaucoma Surgery Trabeculectomy Sclerostomy Migs

ClinConnect Summary

This clinical trial, called the Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study, is looking at patients who have had a specific eye surgery called the MIMS® inferonasal procedure for open-angle glaucoma. The goal is to collect information on how these patients are doing 24 to 30 months after their surgery. Researchers want to understand the long-term effects of this procedure and how it helps manage glaucoma, a condition that can cause vision loss if not treated.

To participate in this study, you need to have had the MIMS® inferonasal surgery at least 24 months ago. The trial is open to all adults, regardless of age or gender. If you qualify and choose to take part, you can expect to share your experiences and any changes in your vision and overall health with the research team. This study is currently recruiting participants, and your involvement could help improve treatment options for others with glaucoma in the future!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Subject who underwent MIMS® inferonasal procedure, and surgery was performed not earlier than 24 months from enrollment

About Sanoculis Ltd

Sanoculis Ltd. is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for ocular diseases. With a strong focus on research and development, Sanoculis leverages cutting-edge science and technology to address unmet medical needs in the field of ophthalmology. Committed to improving patient outcomes, the company collaborates with leading experts and institutions to drive clinical trials that explore novel treatment options. Sanoculis aims to enhance the quality of life for individuals affected by vision-related conditions through its robust pipeline of therapeutic candidates.

Locations

Yerevan, , Armenia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported